Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study
- PMID: 26554655
- PMCID: PMC4705888
- DOI: 10.1038/bjc.2015.377
Reproductive factors and epithelial ovarian cancer survival in the EPIC cohort study
Abstract
Background: Reproductive factors influence the risk of developing epithelial ovarian cancer (EOC), but little is known about their association with survival. We tested whether prediagnostic reproductive factors influenced EOC-specific survival among 1025 invasive EOC cases identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which included 521,330 total participants (approximately 370,000 women) aged 25-70 years at recruitment from 1992 to 2000.
Methods: Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.
Results: After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC. We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR=0.80, 95% CI=0.62-1.03) and a significant survival benefit in long-term MHT users (⩾5 years use vs never use, HR=0.70, 95% CI=0.50-0.99, P(trend)=0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors, including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with EOC-specific mortality risk.
Conclusions: Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.
References
-
- Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A, Marcos-Gragera R, Stiller C, Silva Azevedo E, Chen WQ, Ogunbiyi OJ, Rachet B, Soeberg MJ, You H, Matsuda T, Bielska-Lasota M, Storm H, Tucker TC, Coleman MP (2014) Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385(9972): 977–1010. - PMC - PubMed
-
- Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609): 303–314. - PubMed
-
- Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71(4): 717–721. - PubMed
-
- Cunat S, Hoffmann P, Pujol P (2004) Estrogens and epithelial ovarian cancer. Gynecol Oncol 94(1): 25–32. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 16491/CRUK_/Cancer Research UK/United Kingdom
- C8221/A19170/CRUK_/Cancer Research UK/United Kingdom
- G1000143/MRC_/Medical Research Council/United Kingdom
- 1000143/MRC_/Medical Research Council/United Kingdom
- MC_UU_12015/1/MRC_/Medical Research Council/United Kingdom
- MC_U106179471/MRC_/Medical Research Council/United Kingdom
- G0401527/MRC_/Medical Research Council/United Kingdom
- MR/M012190/1/MRC_/Medical Research Council/United Kingdom
- 001/WHO_/World Health Organization/International
- 14136/CRUK_/Cancer Research UK/United Kingdom
- C570/A16491/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical